Equities analysts expect Sutro Biopharma, Inc. (NASDAQ:STRO – Get Rating) to post earnings per share (EPS) of ($0.78) for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Sutro Biopharma’s earnings. The lowest EPS estimate is ($0.95) and the highest is ($0.52). Sutro Biopharma posted earnings of ($0.43) per share during the same quarter last year, which indicates a negative year over year growth rate of 81.4%. The firm is scheduled to announce its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that Sutro Biopharma will report full-year earnings of ($3.15) per share for the current fiscal year, with EPS estimates ranging from ($4.00) to ($2.19). For the next financial year, analysts anticipate that the business will report earnings of ($3.30) per share, with EPS estimates ranging from ($4.71) to ($2.27). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow Sutro Biopharma.
Sutro Biopharma (NASDAQ:STRO – Get Rating) last released its quarterly earnings results on Monday, February 28th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.09). Sutro Biopharma had a negative return on equity of 32.96% and a negative net margin of 170.55%.
Shares of NASDAQ STRO traded down $0.37 during midday trading on Monday, hitting $6.89. The company’s stock had a trading volume of 3,562 shares, compared to its average volume of 571,594. The company’s fifty day simple moving average is $8.51. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.06. The stock has a market cap of $319.57 million, a price-to-earnings ratio of -3.01 and a beta of 0.97. Sutro Biopharma has a one year low of $7.20 and a one year high of $23.70.
In other news, CEO William J. Newell purchased 10,000 shares of the company’s stock in a transaction on Monday, March 14th. The stock was acquired at an average price of $7.75 per share, with a total value of $77,500.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 5.10% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Meeder Asset Management Inc. raised its holdings in Sutro Biopharma by 19.8% in the 3rd quarter. Meeder Asset Management Inc. now owns 3,609 shares of the company’s stock worth $68,000 after purchasing an additional 596 shares in the last quarter. Point72 Hong Kong Ltd increased its stake in shares of Sutro Biopharma by 99.3% in the 3rd quarter. Point72 Hong Kong Ltd now owns 1,329 shares of the company’s stock worth $25,000 after acquiring an additional 662 shares in the last quarter. Metropolitan Life Insurance Co NY increased its stake in shares of Sutro Biopharma by 5.6% in the 3rd quarter. Metropolitan Life Insurance Co NY now owns 12,710 shares of the company’s stock worth $240,000 after acquiring an additional 679 shares in the last quarter. Royal Bank of Canada increased its stake in shares of Sutro Biopharma by 206.2% in the 3rd quarter. Royal Bank of Canada now owns 1,329 shares of the company’s stock worth $25,000 after acquiring an additional 895 shares in the last quarter. Finally, Deutsche Bank AG increased its stake in shares of Sutro Biopharma by 2.5% in the 4th quarter. Deutsche Bank AG now owns 57,150 shares of the company’s stock worth $850,000 after acquiring an additional 1,396 shares in the last quarter. Institutional investors and hedge funds own 94.51% of the company’s stock.
About Sutro Biopharma (Get Rating)
Sutro Biopharma, Inc operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials.
- Get a free copy of the StockNews.com research report on Sutro Biopharma (STRO)
- Banking On Bank Of America
- Major Shareholder Bets Big On Nielson Holdings plc
- Tapestry Stock is a Value Play Down Here
- Levi Straus Stock Ready to Buy the Dip
- Bed Bath & Beyond Stock Ready to Scale Into
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.